^○Shuichi UEDA¹, Yasushi KAWAMATA², Ayuka EHARA¹, Tsuyoshi YAMAGUCHI¹, Yoshiteru SEO³, Kazutaka SHIMODA² (1. Department of Histology and Neurobiology, Dokkyo Medical University School of Medicine, Tochigi, Japan, 2. Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan, 3. Department of Regulatory Physiology, Dokkyo Medical University School of Medicine, Tochigi, Japan)

^○Hiroko IKEDA¹, Aimi YAMAGISHI¹, Naomi YONEMOCHI¹, Takatsune SHIMIZU², Akihiro MUTO², Junzo KAMEI³ (1. Department of Pathophysiology and Therapeutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan, 2. Department of Pathophysiology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan, 3. Department of Biomolecular Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan)

^○Hideo HAGIHARA, Hirotaka SHOJI, Yoshihiro TAKAMIYA, Tsuyoshi MIYAKAWA (Division of Systems Medicsl Science, Institute for Comprehensive Medical Science, Fujita Health University, Aichi, Japan)

^○Ryuto HARA, Tatsuhiro TAKEHARA, Daiki TAKAHASHI, Saki MINAMI, Taiju AMANO, Masabumi MINAMI (Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan)

^○Shuhei KAYASHIMA^{1, 2}, Hiroshi KUNIISHI¹, Kazumi YOSHIZAWA², Masayuki SEKIGUCHI³, Mitsuhiko YAMADA¹ (1. Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 2. Laboratory of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan, 3. Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan)

^○Mikio YOSHIDA¹, Sho HASEGAWA¹, Mizuki UCHIDA¹, Yoji UCHIDA¹, Akihiro MOURI^{2, 6}, Akira YOSHIMI^{1, 3}, Masayoshi MISHINA⁴, Norio OZAKI³, Toshitaka NABESHIMA^{5, 6}, Yukihiro NODA^{1, 3, 6} (1. Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, Japan, 2. Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Graduate School of Health Sciences, Fujita Health University, Aichi, Japan, 3. Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan, 4. Brain Science Laboratory, The Research Organization of Science and Technology, Ritsumeikan University, Shiga, Japan, 5. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, Aichi, Japan, 6. Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan )

^○Kazuki TOKORO¹, Kyosuke UNO^{1, 2}, Shin-ichi MURAMATSU^{3, 4}, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan., 2. Laboratory of molecular pharmacology faculty of pharmaceutical science, University of Setsunan, Osaka, Japan, 3. Division of Neurology, Department of Medicine, Jichi Medical University, Shimotsuke, JAPAN, 4. Center for Gene and Cell Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, JAPAN)